By contrast, application of HMGB1 inhibitors when restoring p53 in cancer therapy might protect against pro-tumorigenic effects while leaving p53-mediated clearance of cancer cells intact [71], indicating the active function of the p53-binding domain in HMGB1 protein. This evidence concerns the gene TP53 and cancer.